Integrative discovery of treatments for high-risk neuroblastoma
We find more than 80 targets to be associated with neuroblastoma risk and differentiation signatures.
Integrative discovery of treatments for high-risk neuroblastoma has identified more than 80 targets that are associated with neuroblastoma risk and differentiation signatures. By combining predictive data mining with experimental evaluation in patient‑derived xenograft cells, the proposed algorithm, TargetTranslator, integrates data from tumour biobanks, pharmacological databases, and cellular networks to predict how targeted interventions affect mRNA signatures associated with high patient risk or disease processes. The study demonstrates that targeting MAPK8 and CNR2 can suppress tumour growth in zebrafish and mouse xenograft models of high‑risk neuroblastoma.
This claim demonstrates that data‑driven integrative analysis can uncover novel therapeutic targets for high‑risk neuroblastoma, a paediatric cancer with limited effective treatment options.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
- Treatment and Survival of Childhood Neuroblastoma: Evidence from a Population-Based Study in the United States
- Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study